Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3517667 | 0.94 | CYP1A2 (0.52) | CYP1A2ALDH1A1TRPA1KMT2APOLB | |
| SCHEMBL10578789 | 0.92 | CYP1A2 (0.50) | CYP1A2ALDH1A1TRPA1KMT2APOLB | |
| SCHEMBL15009773 | 0.92 | CYP1A2 (0.50) | CYP1A2ALDH1A1TRPA1KMT2APOLB | |
| SCHEMBL2715956 | 0.92 | CYP1A2 (0.50) | CYP1A2ALDH1A1TRPA1KMT2APOLB | |
| SCHEMBL1206813 | 0.88 | L3MBTL1 (0.50) | CYP1A2ALDH1A1TRPA1KMT2APOLB | |
| SCHEMBL27809939 | 0.86 | CYP1A2 (0.55) | CYP1A2ALDH1A1TRPA1KMT2APOLB | |
| SCHEMBL127142 | 0.83 | CYP1A2 (0.57) | CYP1A2ALDH1A1TRPA1KMT2APOLB | |
| SCHEMBL9263719 | 0.82 | CYP1A2 (0.52) | CYP1A2ALDH1A1TRPA1KMT2APOLB | |
| SCHEMBL21262163 | 0.82 | CYP1A2 (0.52) | CYP1A2ALDH1A1TRPA1KMT2APOLB | |
| SCHEMBL1674842 | 0.82 | CYP1A2 (0.52) | CYP1A2ALDH1A1TRPA1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20240352027-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2024-10-24 | — | — | US | disclosed |
| EP-4313991-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117295747-A | Anti-cancer nuclear hormone receptor targeting compounds | 诺维逊生物股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| CN-116685594-A | Triarylborane catalysts and methods for selective hydrosilylation of esters and lactones using the same | 阿尔迪斯化学有限责任公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20220340587-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-10-27 | — | — | US | disclosed |
| WO-2022204184-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| CN-105418412-B | Hypoglycemic activity compound and its medical usage | 中国人民解放军军事医学科学院毒物药物研究所 | 2018-07-06 | — | — | CN | disclosed |
| CN-105418412-A | Hypoglycemic active compound and pharmaceutical application thereof | INST PHARMACOLOGY & TOXICOLOGY ACAD MILITARY MEDICAL SCIENCES PLA CHINA | 2016-03-23 | — | — | CN | disclosed |
| EP-0917528-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | Astra Aktiebolag (SE) | 1999-05-26 | — | — | EP | disclosed |
| EP-0573498-B1 | ALIPHATIC PROPARGYLAMINES AS SELECTIVE MAO-B INHIBITORS AND AS NEUROPROTECTIVE AGENTS | UNIV SASKATCHEWAN (CA) | 1998-11-18 | — | — | EP | disclosed |
| US-5760032-A | GASTROINTESTINAL DISORDERS AND NERVOUS SYSTEM DISORDERS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-06-02 | — | — | US | disclosed |
| WO-1998001422-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-01-15 | — | — | WO | disclosed |
| EP-0776892-A1 | THIENYLAZOLE COMPOUND AND THIENOTRIAZOLODIAZEPINE COMPOUND | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-06-04 | — | — | EP | disclosed |
| US-5508311-A | Aliphatic propargylamines as selective MAO-B inhibitors and as neuroprotective agents | UNIVERSITY OF SASKATCHEWAN (CA) | 1996-04-16 | — | — | US | disclosed |
| EP-0573498-A1 | ALIPHATIC PROPARGYLAMINES AS SELECTIVE MAO-B INHIBITORS AND AS NEUROPROTECTIVE AGENTS | UNIVERSITY OF SASKATCHEWAN (CA) | 1993-12-15 | — | — | EP | disclosed |
| WO-1992015551-A1 | ALIPHATIC PROPARGYLAMINES AS SELECTIVE MAO-B INHIBITORS AND AS NEUROPROTECTIVE AGENTS | UNIVERSITY OF SASKATCHEWAN (CA) | 1992-09-17 | — | — | WO | disclosed |
| US-4885373-A | AMINE DERVIVATIVES USED AS ANTIDEPRESSANT AND DOPAMINERGIC STIMULANTS | ADIR ET CIE (FR) | 1989-12-05 | — | — | US | disclosed |
| US-4863951-A | ANTIDEPRESSANTS, ANTIAGRESSIVES, DOPAMINERGIC PROPERTIES | ADIR ET CIE (FR) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352027-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | CYP1A2 4095/4885ALDH1A1 3398/4885TRPA1 4734/4885 |
| US-20220340587-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | CYP1A2 4095/4885ALDH1A1 3398/4885TRPA1 4734/4885 |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | CYP1A2 4095/4885ALDH1A1 3398/4885TRPA1 4734/4885 |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR3C1, NCOR1 | CYP1A2 3558/4885ALDH1A1 2758/4885TRPA1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.